Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5208806

Cc1cccc2sc(C(N)=O)nc12.NCc1cccc(C(=O)N(CC(=O)O)c2ccccc2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.37
LMNA P02545 4/20 0.37
TP53 P04637 2/20 0.37
POLB P06746 2/20 0.37
F2 P00734 4/20 0.36
ATM Q13315 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MITF O75030 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KLK1 P06870 1/20 0.34
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7432339 0.95 LMNA (0.37) MAPTLMNATP53POLBF2
Trifluoroacetic Acid SCHEMBL5211772 0.91 RAD52 (0.41) MAPTLMNATP53POLBF2
Trifluoroacetic Acid SCHEMBL5204087 0.90 LMNA (0.37) MAPTLMNATP53F2MEN1
Trifluoroacetic Acid SCHEMBL5210737 0.89 F2 (0.38) MAPTF2MEN1KMT2AKLK1
Trifluoroacetic Acid SCHEMBL5211180 0.88 NPC1 (0.39) MAPTLMNATP53F2GAA
Trifluoroacetic Acid SCHEMBL5209105 0.86 TP53 (0.38) MAPTLMNATP53F2MEN1
Trifluoroacetic Acid SCHEMBL5207641 0.85 RAD52 (0.42) MAPTLMNATP53POLBF2
Trifluoroacetic Acid SCHEMBL5205875 0.85 RAD52 (0.40) MAPTTP53F2MEN1KMT2A
Trifluoroacetic Acid SCHEMBL5207907 0.84 MAPT (0.43) MAPTLMNATP53POLBF2
SCHEMBL5207728 0.83 NPC1 (0.43) MAPTLMNATP53F2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343561-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
EP-1343561-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-09-17 EP disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed
WO-2002047762-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 MAPT 4112/4885LMNA 563/4885TP53 3136/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 MAPT 4440/4885LMNA 865/4885TP53 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.